aunque existen ya tests comerciales para detectar ctDNA en este contexto, pido cautela. No deberían usarse sin tener claro su utilidad clínica. Es decir, qué haremos distinto si sale positivo o negativo? hoy en dia no lo sabemos. Necesitamos datos de estud
RT @notSoJunkDNA: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https:/…
RT @prat_aleix: 2 estudios (https://t.co/u1Frfa1CtW https://t.co/FxNQvEO4XH) demuestran que la biopsia líquida en cáncer mama precoç tiene…
RT @prat_aleix: 2 estudios (https://t.co/u1Frfa1CtW https://t.co/FxNQvEO4XH) demuestran que la biopsia líquida en cáncer mama precoç tiene…
2 estudios (https://t.co/u1Frfa1CtW https://t.co/FxNQvEO4XH) demuestran que la biopsia líquida en cáncer mama precoç tiene validez clínica (identifica grupos distintos). Ahora a demostrar validez analítica y, más difícil, utilidad clínica. Los ensayos nos
RT@sciencemagazine Patient-specific monitoring of #breastcancer further advances efforts for #personalizedmedicine
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @DraAnaCasas: ctDNA tracking could enable individualized clinical management of patients w/cancer treated with curative intent. @_SOLTI…
RT @MuinJKhoury: #TARDIS A promising “liquid biopsy” personalized approach to detect circulating tumor DNA for residual disease after breas…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @MustafaRaoofMD: This is transformative.. great to see this in print. Congrats @MurtazaMDPhD and team @tgen @cityofhope .. a blood test…
RT @MustafaRaoofMD: This is transformative.. great to see this in print. Congrats @MurtazaMDPhD and team @tgen @cityofhope .. a blood test…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
TARDIS: Targeted digital sequencing for personalized ctDNA analysis to detect residual disease post drug-treatment in breast cancer patients. Beautiful work by @MurtazaMDPhD & co. https://t.co/Gu57jDH2oI https://t.co/rGmdOnEOV2
This is transformative.. great to see this in print. Congrats @MurtazaMDPhD and team @tgen @cityofhope .. a blood test that may one day enable forgoing surgery altogether
A milestone paper by our very own @MurtazaMDPhD on circulating DNA test for residual disease in breast cancer patients. A significant step towards #PersonalizedMedicine. #ctDNA @AKUGlobal
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @scipak_es: Un ensayo personalizado supera los límites para detectar ADN tumoral en pacientes con cáncer de mama @Cambridge_Uni @TGen ht…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @DraAnaCasas: ctDNA tracking could enable individualized clinical management of patients w/cancer treated with curative intent. @_SOLTI…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
@StoverLab @igmurillas @ICR_London A similar study in #bcsm looking at neoadjuvant responses and ctDNA https://t.co/jiT08dg6gM
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
TARDIS is out! Great work from @TGen’s #murtaza lab collaboration with #slavin and #weitzel @cityofhope. https://t.co/WmHsFUCtxn @montypal @stacywgray @JackWestMD @rrockne
#TARDIS A promising “liquid biopsy” personalized approach to detect circulating tumor DNA for residual disease after breast cancer treatment. Via @ScienceTM https://t.co/dQxutzzyTX https://t.co/nLVvU7yWjX
RT @apwiita: New approach for using cell-free tumor DNA to monitor response to chemotherapy #genomics #ctDNA https://t.co/9PNycmB8cu
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
New approach for using cell-free tumor DNA to monitor response to chemotherapy #genomics #ctDNA https://t.co/9PNycmB8cu
I find it humbling that I am friends with impressive people like @MurtazaMDPhD who has published a stunning study tonight with potential ramifications for clinical practice.
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
Awesome!! game changing work in #cancer
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
Another fantastic breakthrough by @MurtazaMDPhD lab to move the field forward! Congratulations! “Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer” @AKUGlobal @NabeelZafarMD @MustafaRaoofMD
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @DraAnaCasas: ctDNA tracking could enable individualized clinical management of patients w/cancer treated with curative intent. @_SOLTI…
RT @notSoJunkDNA: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https:/…
RT @DraAnaCasas: ctDNA tracking could enable individualized clinical management of patients w/cancer treated with curative intent. @_SOLTI…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
Science feat. Doctor Who. I REALLY LOVE IT.
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @sciencemagazine: Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which…
RT @MurtazaMDPhD: our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/…
Scientists have developed a personalized platform tailored to patients’ specific #cancer mutations named TARDIS, which was able to accurately detect circulating tumor #DNA (ctDNA) and signs of residual disease in 33 women with breast cancer. https://t.co/E
our paper is now online @ScienceTM. Personalized ctDNA analysis to detect residual disease in breast cancer https://t.co/UpZAtCbfHG. A big thank you to my team @TGen @BRMcDonald28, to our collaborators @MayoClinic @CRUK_CI @cityofhope
RT @DraAnaCasas: ctDNA tracking could enable individualized clinical management of patients w/cancer treated with curative intent. @_SOLTI…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
ctDNA tracking could enable individualized clinical management of patients w/cancer treated with curative intent. @_SOLTI @prat_aleix @MBC_Project @MetastaticOdds “Personalized ctDNA analysis to detect residual disease after N/A therapy in breast cancer” h
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
Un ensayo personalizado supera los límites para detectar ADN tumoral en pacientes con cáncer de mama @Cambridge_Uni @TGen https://t.co/qv8Lc3ee2d
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
RT @EricTopol: @NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disea…
@NatureBiotech @Cormac_Sheridan The field is moving so fast that there is another advance today for detecting residual disease in patients following treatment for breast #cancer https://t.co/5OIIxMLqAA @TGen and collaborators @ScienceTM https://t.co/A9yB8t
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.co/mkGkLdne2R
The current real application of liquid biopsy to date https://t.co/5x8sMZkwpa
[Research Articles] Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.co/aKJL3pSVmt
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer https://t.co/WDR8GLwKMF